Tvardi Therapeutics (TVRD) Research & Development: 2013-2017
Historic Research & Development for Tvardi Therapeutics (TVRD) over the last 5 years, with Sep 2017 value amounting to $9.2 million.
- Tvardi Therapeutics' Research & Development fell 5.38% to $9.2 million in Q3 2017 from the same period last year, while for Sep 2017 it was $57.2 million, marking a year-over-year increase of 56.59%. This contributed to the annual value of $49.3 million for FY2016, which is 132.10% up from last year.
- Latest data reveals that Tvardi Therapeutics reported Research & Development of $9.2 million as of Q3 2017, which was up 31.46% from $7.0 million recorded in Q2 2017.
- In the past 5 years, Tvardi Therapeutics' Research & Development ranged from a high of $20.8 million in Q1 2017 and a low of $922,000 during Q1 2013.
- In the last 3 years, Tvardi Therapeutics' Research & Development had a median value of $8.5 million in 2016 and averaged $9.8 million.
- As far as peak fluctuations go, Tvardi Therapeutics' Research & Development skyrocketed by 167.93% in 2016, and later plummeted by 35.31% in 2017.
- Over the past 5 years, Tvardi Therapeutics' Research & Development (Quarterly) stood at $2.0 million in 2013, then soared by 74.87% to $3.5 million in 2014, then surged by 118.79% to $7.6 million in 2015, then surged by 167.93% to $20.3 million in 2016, then declined by 5.38% to $9.2 million in 2017.
- Its Research & Development was $9.2 million in Q3 2017, compared to $7.0 million in Q2 2017 and $20.8 million in Q1 2017.